Millions urged to book new jab that prevents killer lung infection today or risk death – are you eligible? --[Reported by Umva mag]

MILLIONS of Brits have been urged to book a lifesaving new jab that offers 86 per cent protection against a killer lung infections, studies show.

Scientists behind the research say 2,800 deaths could be prevented every year if 70 per cent of eligible adults took up the offer of a vaccine.

Getty

The respiratory syncytial virus (RSV) is a common cause of coughs and colds that can be particularly dangerous to some.

Babies, adults over 75, people with heart and lung disease or anyone with a weak immune system is at greater risk of severe RSV infection and may need admission to hospital, particularly in the winter months.

RSV can cause serious lung infections in very young infants, but growing evidence also shows that the virus can cause serious chest infections in older adults.

The super-common virus is estimated to result in 8,000 deaths in the UK every year.

The NHS rolled out vaccines offering protection against the sometimes deadly virus across England earlier this month.

Anyone aged between 75 and 79 is eligible for one dose of Pfizer‘s jab Abrysvo, as are women who are at least 28 weeks pregnant – a shot of the RSV vaccine can keep them and their babies safe.

Now, new research from the University of Aberdeen and the MRC-University of Glasgow Centre for Virus Research found the vaccines to be 86 percent effective in preventing RSV-related lower respiratory tract infections in the first year after vaccination. 

The team reviewed evidence on how effective RSV vaccines were for older adults and people with weak immune systems.

Their analysis showed that if 70 percent of eligible adults were to have the RSV vaccine, up to 2,800 deaths could be prevented in the UK every year. 

Prof Roy Soiza, who led the research at the University of Aberdeen, said: “Our review found that the vaccines are safe and effective and we are calling on healthcare professionals and carers to encourage those invited to receive the vaccine to take up the opportunity.   

“There is evidence of effectiveness in preventing RSV-related lower respiratory tract infections of around 86 percent in the first year after vaccination.  

“Trials have been conducted in people aged over 60 years of age, including those with underlying medical conditions, but the number of volunteers aged 80 or over was too small to be certain of the extent of benefit.

“Nevertheless, we saw in the Covid pandemic that the effectiveness of vaccines in trials of younger and healthier people was replicated in those who were much frailer and older.   

“We therefore urge those with an interest in the care of older people to encourage those eligible and invited to have the new vaccine to take it.” 

Researchers also found that around 36,000 GP consultations, 4,600 hospitalisations and 1,000 ICU admissions could be avoided if 70 per cent of eligible adults had their RSV vaccine.

At present, RSV is behind 175,000 GP interventions every year.

“The NHS is badly stretched, so efforts to reduce the healthcare burden from avoidable communicable diseases such as RSV infection are highly desirable,” Prof Soiza added.

He called on healthcare professionals to spread the word about the the effectiveness of the RSV vaccine.

“Although some sections of social media are often dominated by anti-vaccine messages, it is important that reliable public health messages cut through the noise,” he explained.

It comes after the NHS invited Brits to book lifesaving flu and Covid-19 vaccines, ahead of a looming winter illness “tripledemic”.

Booking for the vaccines opened on September 23 and they’ll begin to be administered on October 3.

‘SIGNIFICANT STEP’

Scotland also recently rolled out its RSV vaccination programme too, inviting adults over 75 and pregnant women to book the jab in August.

Dr Sam Ghebrehewet, Head of Immunisation and Vaccination at Public Health Scotland, described the launch as a “significant step forward to protect the health of the population”.    

He said: “RSV can be very serious for those who are more vulnerable, such as older adults.

“In recent years, we’ve seen an increase in those aged 75 years and over being hospitalised for RSV.

“That’s why we’re asking all those who are eligible for the RSV vaccine to take up the offer to protect themselves against the more serious complications of an RSV infection.”

Antonia Ho, Professor of Infectious Diseases at the MRC-University of Glasgow Centre for Virus Research, who collaborated on the research said: “The availability of the first effective RSV vaccines in the UK is really exciting.

“Along with existing influenza and Covid-19 vaccines, they will allow us to protect vulnerable groups from serious lung infections, and reduce the enormous pressures faced by the NHS in the winter months.

“The vaccination catch-up campaign for 76-79 years is due to end on 30 September 2024 and I would urge those who are eligible to attend their vaccination appointment.”

The following news has been carefully analyzed, curated, and compiled by Umva Mag from a diverse range of people, sources, and reputable platforms. Our editorial team strives to ensure the accuracy and reliability of the information we provide. By combining insights from multiple perspectives, we aim to offer a well-rounded and comprehensive understanding of the events and stories that shape our world. Umva Mag values transparency, accountability, and journalistic integrity, ensuring that each piece of content is delivered with the utmost professionalism.